Michigan Medicine News Break

An early clinical trial at U-M finds that a Wee1 inhibitor, combined with radiation and gemcitabine, is safe and potentially effective in pancreatic cancer treatment. Investigators ran a phase 1 clinical trial that looked at AZD1775, an inhibitor designed to block an enzyme called Wee1, which plays a role in repairing damaged DNA. The trial builds on almost 20 years of research at U-M focused on improving the treatment of pancreatic cancer cases that are too advanced for surgery.For more information about this story visit: https://labblog.uofmhealth.org/lab-report/new-drug-shows-encouraging-survival-results-for-pancreatic-cancer See acast.com/privacy for privacy and opt-out information.